

July 15, 2025

The Honorable Mike Kennedy
United States House of Representatives
Washington, DC 20510

Dear Representative Kennedy:

On behalf of the Pain Medicine Coalition (PMC), whose members include the American Society of Anesthesiologists (ASA), the American Society of Regional Anesthesia and Pain Medicine (ASRA Pain Medicine), the International Pain and Spine Intervention Society (IPSIS), and the American Academy of Physical Medicine and Rehabilitation (AAPM&R), we are writing to express our endorsement of the **Safe Prescribing Through Reporting Act of 2025 (H.R.3595)**.

The PMC represents over 75,000 physicians dedicated to advancing evidence-based pain management for patients. Specifically, the PMC strongly supports efforts to ensure the safety of patients receiving pain medicine therapies and prescriptions, which requires pain medicine physicians to have a comprehensive medical history, including knowledge of any current prescriptions, which also includes substance use disorder medications.

The PMC strongly believes that it is vital for the safety of our patients that physicians have all of the crucial health information when prescribing to patients. This is of particular concern with patients who are taking medications to treat substance use disorder (e.g., Methadone). As current federal law does not require that substance abuse clinics report to the Prescription Drug Monitoring Programs (PDMPs), physicians are not guaranteed accurate prescription information for these types of medications. The potential risks for drug interactions that could risk the patient's health and safety are high, especially when narcotics are involved.

We support the efforts of this bill to enhance transparency and patient safety by allowing substance abuse disorder medications to be reported in the state's PDMP when authorized by state law. By ensuring accurate information about medications and dosage, appropriate care decisions can be made that can anticipate and minimize dangerous drug interactions.

With the safety of our patients in mind, the PMC endorses the Safe Prescribing Through Reporting Act of 2025 (H.R.3595) and its goal of ensuring that physicians are equipped with accurate information about a patient's substance use disorder medications before treating them with additional medications.

The PMC applauds your leadership in addressing this gap in federal law that will add a layer of protection for patients being treated for substance use disorders from potentially dangerous drug interactions. We are committed to working with you on advancing this bill that would meaningfully improve the state of patient care and patient safety in the country.

If you have any questions or would like to discuss further, please do not hesitate to contact Elizabeth Smith at esmith@asra.com and Allison Kronback at a.kronback@asahq.org.

Sincerely,

A handwritten signature in black ink, appearing to read "D. E. Arnold".

Donald E. Arnold, MD, FACHE, FASA
President, American Society of Anesthesiologists

A handwritten signature in cursive script, reading "Steven Cohen".

Steven Cohen, MD
President, American Society of Regional Anesthesia and Pain Medicine

A handwritten signature in cursive script, reading "Joshua Rittenberg".

Joshua Rittenberg, MD,
President, International Pain and Spine Intervention Society

A handwritten signature in cursive script, reading "Scott R. Laker".

Scott R. Laker, MD, FAAPMR
President, American Academy of Physical Medicine and Rehabilitation